Skip to content

Fabry Disease Registry & Pregnancy Sub-registry

Fabry Disease

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.

The primary objectives of the Registry are:

* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
* To characterize and describe the Fabry population as a whole;
* To evaluate the long-term safety and effectiveness of Fabrazyme®

Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria

* Fabry Registry: All patients with a confirmed diagnosis of Fabry disease who have signed the informed consent and patient authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte αGAL (alpha-galactosidase) enzyme activity and/or mutation(s) in the gene coding for αGAL.
* Fabry Pregnancy Sub-registry:

* Eligible women must:

* be enrolled in the Fabry Registry.
* be pregnant, or have been pregnant with appropriate medical documentation available.
* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.

Exclusion Criteria Fabry Registry: There are no exclusion criteria. Fabry Pregnancy Sub-registry: There are no exclusion criteria.

Study Location

Investigational Site Number : 124011
Investigational Site Number : 124011
Vancouver, British Columbia
Canada

Contact Study Team

Investigational Site Number : 124008
Investigational Site Number : 124008
Halifax, Nova Scotia
Canada

Contact Study Team

Investigational Site Number : 124009
Investigational Site Number : 124009
Toronto, Ontario
Canada

Contact Study Team

Investigational Site Number : 124010
Investigational Site Number : 124010
Vancouver, British Columbia
Canada

Contact Study Team

Investigational Site Number : 124023
Investigational Site Number : 124023
St. John's, Newfoundland and Labrador
Canada

Contact Study Team

Investigational Site Number : 124006
Investigational Site Number : 124006
Toronto, Ontario
Canada

Contact Study Team

Investigational Site Number : 124014
Investigational Site Number : 124014
Calgary, Alberta
Canada

Contact Study Team

Investigational Site Number : 124019
Investigational Site Number : 124019
Winnipeg, Manitoba
Canada

Contact Study Team

Investigational Site Number : 124005
Investigational Site Number : 124005
Kingston, Ontario
Canada

Contact Study Team

Investigational Site Number : 124013
Investigational Site Number : 124013
Montreal, Quebec
Canada

Contact Study Team

Investigational Site Number : 124002
Investigational Site Number : 124002
Edmonton, Alberta
Canada

Contact Study Team

Investigational Site Number : 124022
Investigational Site Number : 124022
Moncton, New Brunswick
Canada

Contact Study Team

Investigational Site Number : 124021
Investigational Site Number : 124021
London, Ontario
Canada

Contact Study Team

Investigational Site Number : 124001
Investigational Site Number : 124001
Sherbrooke, Quebec
Canada

Contact Study Team

Study Sponsored By
Sanofi
Participants Required
More Information
Study ID: NCT00196742